Hepatitis D – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Hepatitis D – Drugs In Development, 2024 report and make more profitable business decisions.
Hepatitis D, also known as the delta virus, is an infection that causes the liver to swell. It is caused by the hepatitis D virus (HDV). Symptoms include yellowing of skin and eyes, joint pain, abdominal pains, vomiting, loss of appetite, and fatigue. Risk factors include receiving many blood transfusions, abusing intravenous (IV) or injection drugs, and being infected while pregnant.
The Hepatitis D drugs in development market research report provide comprehensive information on the therapeutics under development for Hepatitis D, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hepatitis D and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Hepatitis D | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 26 molecules, with 23 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Hepatitis D therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Hepatitis D pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Hepatitis D treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Assembly Biosciences IncBluejay Therapeutics Inc
Centre for Drug Design and Discovery
CN Bio Innovations Ltd
Eiger BioPharmaceuticals Inc
Gilead Sciences Inc
Globeimmune Inc
Huahui Health Ltd
Ipsen SA
Johnson & Johnson
PharmaEssentia Corp
Replicor Inc
Rodos BioTarget GmbH
Shanghai HEP Pharmaceutical Co Ltd
SomaGenics Inc
Suzhou Hepa Thera Biopharmaceutical Co Ltd
Suzhou Ribo Life Sciences Co Ltd
Svenska Vaccinfabriken Produktion AB
Tokyo University of Science
University of Tokyo
Vir Biotechnology Inc
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Hepatitis D reports